The effects of sustained virological response to direct‐acting anti‐viral therapy on the risk of extrahepatic manifestations of hepatitis C infection

Direct‐acting anti‐viral (DAA) therapy may have a beneficial role in extrahepatic manifestations of hepatitis C virus (HCV) infection. However, the available data are limited.

[1]  A. Moorman,et al.  Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes , 2019, Alimentary pharmacology & therapeutics.

[2]  M. Stepanova,et al.  Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia , 2019, Alimentary pharmacology & therapeutics.

[3]  Ding‐Shinn Chen,et al.  Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection , 2018, Alimentary pharmacology & therapeutics.

[4]  D. Thabut,et al.  Long‐term Efficacy of Interferon‐Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus–Associated Cryoglobulinemia Vasculitis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  H. El‐Serag,et al.  Real‐world effectiveness of elbasvir/grazoprevir In HCV‐infected patients in the US veterans affairs healthcare system , 2018, Journal of viral hepatitis.

[6]  D. Vergani,et al.  Interferon‐free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis , 2018, Alimentary pharmacology & therapeutics.

[7]  P. Cacoub,et al.  Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis , 2018, Gut.

[8]  E. Bugianesi,et al.  Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents , 2018, Journal of medical virology.

[9]  Z. Younossi,et al.  Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France , 2018, Alimentary pharmacology & therapeutics.

[10]  A. Federico,et al.  Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkin's lymphoma , 2018, Hepatology.

[11]  H. Kokuryu,et al.  Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c , 2017, Digestion.

[12]  L. Sticchi,et al.  Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy , 2017, The Journal of antimicrobial chemotherapy.

[13]  G. Ioannou,et al.  Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus , 2017, Diabetes Care.

[14]  J. Kramer,et al.  The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection , 2017, Gut.

[15]  K. Anderson,et al.  Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda , 2017, The American journal of the medical sciences.

[16]  D. Klatzmann,et al.  Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. , 2017, Gastroenterology.

[17]  R. Bruno,et al.  Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. , 2016, Blood.

[18]  L. Petraccia,et al.  Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia , 2016, Hepatology.

[19]  S. Pol,et al.  Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. , 2016, Annals of the rheumatic diseases.

[20]  G. Ioannou,et al.  Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. , 2016, Gastroenterology.

[21]  M. Stepanova,et al.  Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. , 2016, Gastroenterology.

[22]  D. Sautereau,et al.  HCV‐associated B‐cell non‐Hodgkin lymphomas and new direct antiviral agents , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[23]  K. Reddy,et al.  Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus , 2015, Hepatology.

[24]  H. El‐Serag,et al.  Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. , 2008, Journal of hepatology.

[25]  H. El‐Serag,et al.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. , 2007, JAMA.

[26]  L. Dal Maso,et al.  Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. , 2018, Clinical and experimental rheumatology.

[27]  H. Masur,et al.  No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV , 2017, The Journal of infectious diseases.

[28]  E. Morra,et al.  Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. , 2015, Journal of hepatology.

[29]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .